COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,362 Articles (22,803 medRxiv, 8,559 bioRxiv)

Most recent first Previous |  Page 584: Articles 5831-5840  | Next

Sensible Long-lead Forecast of COVID-19 Epidemic Outcomes
Yang, W., Shaman, J.
10.1101/2022.11.14.22282323 — Posted: 2022-11-15
Detection of infectious SARS-CoV-2 in frozen aerosol samples collected from hospital rooms of patients with COVID-19
Fortin, A., Veillette, M., Larrotta, A., Longtin, Y., Duchaine, C., Grandvaux, N.
10.1101/2022.11.14.22282295 — Posted: 2022-11-15
Using Genome Sequence Data to Predict SARS-CoV-2 Detection Cycle Threshold Values
Duesterwald, L., Nguyen, M., Christensen, P., Long, S. W., Olsen, R. J., Musser, J. M., Davis, J. J.
10.1101/2022.11.14.22282297 — Posted: 2022-11-15
The SARS-CoV-2 protein ORF3c is a mitochondrial modulator of innate immunity
Stewart, H., Lu, Y., O'Keefe, S., Valpadashi, A., Cruz-Zaragoza, L. D., Michel, H. A., Nguyen, S. K., Carnell, G. W., Lukhovitskaya, N., Milligan, R., Jungreis, I., Lulla, V., Davidson, A. D., Matthews, D. A., High, S., Rehling, P., Emmott, E., Heeney, J. L., Edgar, J. R., Smith, G. L., Firth, A. E.
10.1101/2022.11.15.516323 — Posted: 2022-11-15
The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants
Pandit, J. A., Radin, J. M., Chiang, D., Spencer, E. G., Pawelek, J. B., Diwan, M., Roumani, L., Mina, M. J.
10.1101/2022.11.14.22282195 — Posted: 2022-11-15
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting
Chemaitelly, H., Ayoub, H., Tang, P., Coyle, P., YASSINE, H. M., Althani, A., Al-Khatib, H. A., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., Al-Thani, M., Al-Khal, A., Bertollini, R., Faust, J. S., Abu-Raddad, L. J.
10.1101/2022.11.14.22282103 — Posted: 2022-11-15
Risk of SARS-CoV-2 reinfection is time- and variant-dependant, France, January 2021 to August 2022
Auvigne, V., Schaeffer, J., Boudon, T., Tamandjou, C., Figoni, J., Parent du Chatelet, I., Bernard-Stoecklin, S.
10.1101/2022.11.09.22282113 — Posted: 2022-11-15
COVID-19 IN BRAZIL: A CROSS-SECTIONAL IMMUNO-EPIDEMICAL AND GENOMIC EVALUATION IN A PRE-OMICRON ERA
Rodrigues, S. d. O., Ferrari de Oliveira, G., Costa e Silva, M., Pagnossa, J. P.
10.1101/2022.11.12.22282248 — Posted: 2022-11-15
Protection conferred by Delta and BA.1/BA.2 infection against BA.4/BA.5 infection and hospitalization: A Retrospective Cohort Study
Winchester, N., Shrestha, N., Kim, P., Tereshchenko, L. G., Rothberg, M.
10.1101/2022.11.14.22282310 — Posted: 2022-11-14
Risk factors and symptom clusters for Long Covid: analysis of United Kingdom symptom tracker app data.
Ford, E., Parfitt, H., McCheyne, I., Kiss, I., Sellers, R.
10.1101/2022.11.14.22282285 — Posted: 2022-11-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).